Navigation Links
The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments
Date:11/30/2009

NEW YORK, Nov. 30 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announced $1.5 million in total awards to six research teams working to develop potentially disease-modifying therapies for Parkinson's disease. The funding was awarded under the Novel Approaches to Drug Discovery for Parkinson's Disease program, made possible by funding from Elan Corporation, plc (NYSE: ELN), a neuroscience-based biotechnology company.

The Novel Approaches program is an important component of MJFF's overall strategy of providing critical resources to under-funded areas of the drug development pipeline. Novel Approaches seeks to advance the development of therapeutic targets that already have some promising initial data, while engaging industry partner Elan as a potential follow-on funder for those projects with the greatest potential to bring new, transformative treatments to people living with PD.

Awardees under Novel Approaches include both academic and industry scientists. Of the six awardees, two will target the protein alpha-synuclein, whose clumping is a hallmark of PD pathology. The remaining teams are developing technologies to prevent the degeneration of dopaminergic neurons, the main type of cell affected in PD, by focusing on the reduction of oxidative stress and the inhibition of JNK, a protein associated with cell death.

Projects selected for funding are listed below. Grant abstracts and researcher bios are also available on the Foundation's Web site, www.michaeljfox.org. The selection of awardees was made exclusively by the Foundation via its standard peer-review process.

Inhibition of brain-dependent nitric oxide (NO) over-production by isoform-selective NO synthase (NOS) inhibitors

John Andrews, PhD, NeurAxon, Toronto, Ontario, Canada

Development of HSF1 effectors as Parkinson's disease therapeutics

William Janzen, PhD, and Maria Sippola-Thiele, PhD, Chaperone Therapeutics, Durham, North Carolina

Optimizing metalloporphryins for clinical development

Manish Patel, PhD, University of Colorado, Denver, Colorado

Optimization of alpha synuclein 5'UTR directed translation blockers as novel drugs for Parkinson's disease

Jack Rogers, PhD, Mental Health Research Institute of Victoria, Melbourne, Australia

Cerium oxide nanoparticles in treatment of Parkinson's disease

Beverly Rzigalinski, PhD, Virginia College of Osteopathic Medicine, Blacksburg, Virginia

Novel JNK inhibitors as therapeutic agents for Parkinson's disease

Bobby Thomas, PhD, Weill Medical College of Cornell University, New York, New York and Maurizio Pellecchia, PhD, Burnham Institute for Medical Research, La Jolla, California

About The Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded over $158 million in research to date.

About Elan

Elan Corporation, plc (NYSE: ELN) is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Irish Stock Exchanges. For additional information about the company, please visit www.elan.com.

SOURCE The Michael J. Fox Foundation for Parkinson's Research


'/>"/>
SOURCE The Michael J. Fox Foundation for Parkinson's Research
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
3. Genstar Names Michael Hurt to Its Strategic Advisory Board
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
10. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
11. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... Executives and subject matter ... progressive pharma and biotech organizations to do more clinical trials will share best ... in Q4. , DrugDev will demonstrate DrugDev Spark™, the world’s first unified clinical ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... Koch Agronomic Services (Koch) to feature new innovations aimed at helping farmers solve ... quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local ...
(Date:9/20/2017)... (PRWEB) , ... September 20, ... ... recently published findings of a study examining the effects of exoskeleton-assisted walking ... spinal cord injury (SCI). The article, "Neuromechanical adaptations during a robotic powered ...
(Date:9/19/2017)... ... September 19, 2017 , ... Participants of this ... high-performance fume hood. Along with the advantages and disadvantages of ductless, filtered fume ... hoods in the laboratory. , Attendees will learn from an industry expert about ...
Breaking Biology Technology:
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
Breaking Biology News(10 mins):